17th North American Regional ISSX Meeting (October 16 - 20, 2011): Conjugation Reactions and Enzymes

P28

Biotransformation of Abused Synthetic Cannabinoids, JWH-018 and JWH-073, by Human Cytochromes P450 and UDP-glucuronosyltransferases
Anna Radominska-Pandya, University of Arkansas for Medical Science; Krishna C. Chimalakonda, University of Arkansas for Medical Science; Stacie M. Bratton, University of Arkansas for Medical Science; Barbara Fedejko-Kap, University of Arkansas for Medical Science; Vi-Huyen Le, AR Public Health Laboratory; Kan Hui “Nicole” Yiew, University of Arkansas for Medical Science; Cindy Moran, Arkansas State Crime Lab; Laura P. James, Department of Pediatrics; Jeffery H. Moran, AR Public Health Laboratory

P29

Characterization Of In Vitro Glucuronidation Of Five Anthraquinones From Rhubarb
Wenjin Wu, Institute of Chinese Medical Sciences, Universtiy of Macau; Yuelin Song, Institute of Chinese Medical Sciences, Universtiy of Macau; Yaping Li, Institute of Chinese Medical Sciences, Universtiy of Macau; Ru Yan, Institute of Chinese Medical Sciences, Universtiy of Macau; Yitao Wang, Institute of Chinese Medical Sciences, Universtiy of Macau

P30

Comparison of UDP-Glucuronosyltransferase 2B7 Absolute Protein Quantification and Metabolic Activity Using Zidovudine as Selective Probe Substrate
Staffan Thorén, AstraZeneca R&D Södertälje; Marie Wallin, AstraZeneca R&D Södertälje; Johan Lengqvist, AstraZeneca R&D Södertälje; Pawel Baranczewski, AstraZeneca R&D Södertälje

P31

Determination of 7-Hydroxycoumarin Specificity using Recombinant Human Enzymes of Uridine 5'-diphospho-glucuronosyltransferase (UGT)
Timothy A. Moeller, Celsis In Vitro Technologies; Terrel Rose, Celsis In Vitro Technologies; Scott Heyward, Celsis In Vitro Technologies

P32

Effects of Various Incubation Mediums on UDP-Glucuronosyltransferase 2B7 (UGT2B7) Activity
Dustin M. Smith, Boehringer-Ingelheim Pharmaceuticals Inc; Arenas Raquel, Boehringer-Ingelheim Pharmaceuticals Inc; David D. Boyer, Boehringer-Ingelheim Pharmaceuticals Inc; Michael B Fisher, Boehringer-Ingelheim Pharmaceuticals Inc

P33

Evaluation of toxic potential of acylglucuronides by combination of orthogonal factors
Yoshiaki Shimada, Astellas Pharma Inc.; Toshihiro Matsuda, Astellas Pharma Inc.; Kohichiro Tanaka, Astellas Pharma Inc.; Kazuyoshi Nozaki, Astellas Pharma Inc.; Shigeyuki Terashita, Astellas Pharma Inc.; Toshio Teramura, Astellas Pharma Inc.

P34

Evidence for homo-dimerization of UDP-glucuronosyltransferase 2B7 and identification of the dimerization domain by protein homolgy modelling
John O. Miners, Flinders University School of Medicine; Benjamin C. Lewis, Flinders University School of Medicine; Peter I. Mackenzie, Flinders University School of Medicine

P35

Liquid-Chromatographic Mass Spectrometric Quantitation of Uridine 5'-Diphospho-Glucuronosyltransferase (UGT) Enzymes: Analysis of 50 Individual Human Liver Microsomes and Preliminary Statistical Results
Christopher Ray Gibson, Merck & Co Inc; Richard King, PharmaCadence Analytical Services, LLC; Carmen Fernandez-Metzler, PharmaCadence Analytical Services, LLC; Jorge Quiroz, Merck Research Laboratories; Thomas Rushmore, Life Technologies; Kevin Bateman, Merck Research Laboratories

P36

Optimized Assays for Human UDP-Glucuronosyltransferase (UGT) Activities: Altered Alamethicin Concentration and Utility to Identify UGT Inhibitors
Robert L. Walsky, Pfizer Inc.; Jonathan N. Bauman, Pfizer Inc.; Karine Bourcier, Pfizer Inc.; Georgina Giddens, Pfizer Inc.; Kimberly Lapham, Pfizer Inc.; Tim F. Ryder, Pfizer Inc.; R. Scott Obach, Pfizer Inc.; Ruth Hyland, Pfizer Inc.; Theunis C. Goosen, Pfizer Inc.

P37

Prediction of the Metabolic Clearance of a Spiropiperidine BACE1 Inhibitor by Glucuronidation and Cytochrome P450-mediated Oxidations
Jianhua Liu, Pfizer Inc.; Zhuang Miao, Pfizer Global Research and Development; Louis Leung, Pfizer Inc.

P39

Telmisartan Non-selectively Inhibits UDP-glucuronosyltransferase (UGT) 1A and UGT2B Proteins
Kathleen M. Knights, Flinders University; Shane M. Spencer, Flinders University; John O. Miners, Flinders University

P40

The Role of Intestine and Liver in Glucuronidation of the Imidazo- and Triazoloacridinone Antitumor Agents, C-1311 and C-1305: High Affinity Substrates for UGT1A10
Barbara Fedejko-Kap, Gdansk University of Technology; Stacie M. Bratton, University of Arkansas for Medical Science; Moshe Finel, University of Helsinki; Zofia Mazerska, Gdansk University of Technology; Anna Radominska-Pandya, University of Arkansas for Medical Science

P42

Transcriptional diversity at the UGT2B7 locus is dictated by extensive pre-mRNA splicing
Vincent Ménard, Pharmacogenomics Laboratory, CHUQ Research Center and Faculty of Pharmacy, Laval University; Olivier Eap, Pharmacogenomics Laboratory, CHUQ Research Center and Faculty of Pharmacy, Laval University; Joannie Roberge, Pharmacogenomics Laboratory, CHUQ Research Center and Faculty of Pharmacy, Laval University; Mario Harvey, Pharmacogenomics Laboratory, CHUQ Research Center and Faculty of Pharmacy, Laval University; Éric Lévesque, Pharmacogenomics Laboratory, CHUQ Research Center and Faculty of Pharmacy, Laval University; Chantal Guillemette, Pharmacogenomics Laboratory, CHUQ Research Center and Faculty of Pharmacy, Laval University